A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

PM Kasi, CL Maige, F Shahjehan, JM Rodgers… - Frontiers in …, 2019 - frontiersin.org
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide
therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin …

[HTML][HTML] Toxicity and Tolerability of 177Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin–A Phase 2 Registry Study

A Khatami, G Sistani, DEK Sutherland… - Current …, 2022 - ncbi.nlm.nih.gov
Background: Peptide receptor radionuclide therapy (PRRT) has been recently approved for
advanced, metastatic, or progressive neuroendocrine tumors (NETs). Objective: This study …

Long-term outcomes of submaximal activities of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients

NS Minczeles, WW de Herder… - Journal of Nuclear …, 2023 - Soc Nuclear Med
In the literature, up to 45% of neuroendocrine tumor (NET) patients who are treated with
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) do not receive the …

[HTML][HTML] Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors

B Bennett - Number 1/February 2024, 2024 - ons.org
Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse
family of cancers that occur within the gastrointestinal tract and pancreas. Peptide receptor …

Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

M Kalantarhormozi, S Hassanzadeh… - World Journal of …, 2022 - thieme-connect.com
Background This study was conducted to evaluate the clinical efficacy and safety of peptide
receptor radionuclide therapy (PRRT) using 177 Lu-DOTA0-Tyr3-octreotate (DOTATATE) in …

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

M Del Prete, FA Buteau, JM Beauregard - European journal of nuclear …, 2017 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 177 Lu-octreotate is commonly
administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly …

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

MN Becx, NS Minczeles, T Brabander, WW de Herder… - Cancers, 2022 - mdpi.com
Simple Summary Peptide receptor radionuclide therapy (PRRT) is one of the treatment
options for locally advanced or metastatic gastroenteropancreatic (GEP) neuroendocrine …

Efficacy of 177Lu peptide receptor radionuclide therapy for the treatment of neuroendocrine tumors: A meta-analysis

B Saravana-Bawan, A Bajwa, J Paterson… - Clinical nuclear …, 2019 - journals.lww.com
Objective The purpose of this study was to assess the efficacy of 177 Lu-labeled peptide
receptor radionuclide therapy (PRRT) induction treatments for patients with unresectable …

Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment

J Svensson, G Berg, B Wängberg, M Larsson… - European journal of …, 2015 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment
option in the management of advanced neuroendocrine tumours. Long-lasting responses …

PP492 177Lu-DOTATATE peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumors: Asian retrospective analysis

Y Shin, BH Moon, BY Ryoo, HM Chang, KP Kim… - ESMO Open, 2023 - esmoopen.com
Background 177Lu-PRRT is one of standard treatments for pts with somatostatin receptor
(SSTR)-positive well-differentiated NETs. However, only few pts with Asian ethnicity were …